Cargando…
Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs
BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404079/ https://www.ncbi.nlm.nih.gov/pubmed/25889498 http://dx.doi.org/10.1186/s40360-015-0007-z |
_version_ | 1782367440578019328 |
---|---|
author | Saine, M Elle Carbonari, Dena M Newcomb, Craig W Nezamzadeh, Melissa S Haynes, Kevin Roy, Jason A Cardillo, Serena Hennessy, Sean Holick, Crystal N Esposito, Daina B Gallagher, Arlene M Bhullar, Harshvinder Strom, Brian L Re, Vincent Lo |
author_facet | Saine, M Elle Carbonari, Dena M Newcomb, Craig W Nezamzadeh, Melissa S Haynes, Kevin Roy, Jason A Cardillo, Serena Hennessy, Sean Holick, Crystal N Esposito, Daina B Gallagher, Arlene M Bhullar, Harshvinder Strom, Brian L Re, Vincent Lo |
author_sort | Saine, M Elle |
collection | PubMed |
description | BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. METHODS: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD(SM)) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. RESULTS: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRD(SM): 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRD(SM): 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. CONCLUSIONS: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT01086280, NCT01086293, NCT01086319, NCT01086306, and NCT01377935 |
format | Online Article Text |
id | pubmed-4404079 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44040792015-04-21 Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs Saine, M Elle Carbonari, Dena M Newcomb, Craig W Nezamzadeh, Melissa S Haynes, Kevin Roy, Jason A Cardillo, Serena Hennessy, Sean Holick, Crystal N Esposito, Daina B Gallagher, Arlene M Bhullar, Harshvinder Strom, Brian L Re, Vincent Lo BMC Pharmacol Toxicol Research Article BACKGROUND: The patterns and determinants of saxagliptin use among patients with type 2 diabetes mellitus (T2DM) are unknown in real-world settings. We compared the characteristics of T2DM patients who were new initiators of saxagliptin to those who were new initiators of non-dipeptidyl peptidase-4 (DPP-4) inhibitor oral anti-diabetic drugs (OADs) and identified factors associated with saxagliptin use. METHODS: We conducted a cross-sectional study within the Clinical Practice Research Datalink (CPRD), The Health Improvement Network (THIN), US Medicare, and the HealthCore Integrated Research Database (HIRD(SM)) across the first 36 months of saxagliptin availability (29 months for US Medicare). Patients were included if they were: 1) ≥18 years old, 2) newly prescribed saxagliptin or a non-DPP-4 inhibitor OAD, and 3) enrolled in their respective database for 180 days. For each saxagliptin initiator, we randomly selected up to ten non-DPP-4 inhibitor OAD initiators matched on age, sex, and geographic region. Conditional logistic regression was used to identify determinants of saxagliptin use. RESULTS: We identified 64,079 saxagliptin initiators (CPRD: 1,962; THIN: 2,084; US Medicare: 51,976; HIRD(SM): 8,057) and 610,660 non-DPP-4 inhibitor OAD initiators (CPRD: 19,484; THIN: 19,936; US Medicare: 493,432; HIRD(SM): 77,808). Across all four data sources, prior OAD use, hypertension, and hyperlipidemia were associated with saxagliptin use. Saxagliptin initiation was also associated with hemoglobin A1c results >8% within the UK data sources, and a greater number of hemoglobin A1c measurements in the US data sources. CONCLUSIONS: In these UK and US data sources, initiation of saxagliptin was associated with prior poor glycemic control, prior OAD use, and diagnoses of hypertension and hyperlipidemia. TRIAL REGISTRATION: ClinicalTrials.gov identifiers NCT01086280, NCT01086293, NCT01086319, NCT01086306, and NCT01377935 BioMed Central 2015-04-02 /pmc/articles/PMC4404079/ /pubmed/25889498 http://dx.doi.org/10.1186/s40360-015-0007-z Text en © Saine et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Saine, M Elle Carbonari, Dena M Newcomb, Craig W Nezamzadeh, Melissa S Haynes, Kevin Roy, Jason A Cardillo, Serena Hennessy, Sean Holick, Crystal N Esposito, Daina B Gallagher, Arlene M Bhullar, Harshvinder Strom, Brian L Re, Vincent Lo Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
title | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
title_full | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
title_fullStr | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
title_full_unstemmed | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
title_short | Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
title_sort | determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4404079/ https://www.ncbi.nlm.nih.gov/pubmed/25889498 http://dx.doi.org/10.1186/s40360-015-0007-z |
work_keys_str_mv | AT sainemelle determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT carbonaridenam determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT newcombcraigw determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT nezamzadehmelissas determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT hayneskevin determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT royjasona determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT cardilloserena determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT hennessysean determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT holickcrystaln determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT espositodainab determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT gallagherarlenem determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT bhullarharshvinder determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT strombrianl determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs AT revincentlo determinantsofsaxagliptinuseamongpatientswithtype2diabetesmellitustreatedwithoralantidiabeticdrugs |